CompletedNCT00448630
Metabolic health during antipsychotic treatment for schizophrenia
About this title
Read the official source — NCT00448630Observational studyAges 18–55Türkiye
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Kurttepe and 46 more locationsSee all locations and recruitment
Study information
Study start dateStarted: October 23, 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 328
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Observational
- Intervention type
- OTHER
- Study phase
- Not clearly listed
- Locations
- Türkiye
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00448630
- Official title
Show the full official title
A MULTI-CENTER, NON-INVASIVE OBSERVATIONAL STUDY OF METABOLIC SYNDROME PARAMETERS IN SCHIZOPHRENIC PATIENTS USING ATYPICAL ANTIPSYCHOTICS
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kurttepe, Türkiye · Adana, Türkiye · Ankara, Türkiye
14 more locations
- Antakya, Türkiye
- Bolu, Türkiye
- Denizli, Türkiye
- Elâzığ, Türkiye
- Eskişehir, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Kayseri, Türkiye
- Konya, Türkiye
- Manisa, Türkiye
- Samsun, Türkiye
- Trabzon, Türkiye
- Trakya, Türkiye
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Who was this study for?
Listed age limits: 18 years to 55 years.
